Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks bempedoic acid combo in asian and latin american patients

NCT ID NCT07206472

Knowledge-focused Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study is observing over 2,500 adults with high cholesterol who are taking a combination of bempedoic acid and ezetimibe in routine medical care. Researchers are collecting data on side effects and heart risk to better understand how the treatment works in Asian and Latin American populations. No new drug is being given; it simply watches what happens in real-world practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bempedoic acid and ezetimibe combination
What this could lead to
If successful, this study could provide real-world evidence on how well this cholesterol-lowering combination works and its safety in diverse populations.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by other factors and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes adult patients diagnosed with primary hypercholesterolemia or mixed dyslipidemia treated by specialized as well as non-specialized physicians in hospitals and office-based centers from six countries (Brazil, Hong Kong, South Korea, Taiwan, and Thailand).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients can be enrolled, when they fulfil the following inclusion criteria: * Written informed consent to participate. * At least 18 years of age. * Patients suffering from documented primary hypercholesterolemia or mixed dyslipidaemia treated or intended to be treated with bempedoic acid/ FDC with ezetimibe at the discretion of the physician are appropriate for participation in the observation. * For patients who are treated with bempedoic acid/FDC with ezetimibe prior to signed informed consent, initiation of bempedoic acid/FDC with ezetimibe must be within a maximum of three months prior to inclusion. * No contraindications exist according to the SmPC of bempedoic acid/FDC with ezetimibe. * No concurrent participation in an interventional study (simultaneous participation in other non-interventional study is possible) * Life expectancy \> 1 year. No explicit exclusion criteria exist to avoid selection bias and to allow for documentation of routine clinical practice.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mixed dyslipidaemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperlipidemia, familial combined, LPL related inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mixed dyslipidemia Primary hypercholesterolaemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    23 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • BP - A Beneficencia Portuguesa de Sao Paulo

    RECRUITING

    São Paulo, 01323-001, Brazil

  • CMEP Centro Multidisciplinar de Ensino Especializado e Pesquisa LTDA

    RECRUITING

    Joinville, 89204-251, Brazil

  • Cardial Servicos Medicos Especializados

    RECRUITING

    São Paulo, 04039-000, Brazil

  • Clinica Procardio Ltda.

    RECRUITING

    Blumenau, 89010-500, Brazil

  • Fundacao Bahiana de Infectologia

    RECRUITING

    Salvador, 40110-060, Brazil

  • Galileo Medical Research Ltda.

    RECRUITING

    Juiz de Fora, 18270-170, Brazil

  • Hospital Alemao Oswaldo Cruz (HAOC)

    RECRUITING

    São Paulo, 01323-020, Brazil

  • Hospital E Maternidade Dr. Cristavao da Gama (HMCG)

    RECRUITING

    Santo André, 09030-010, Brazil

  • Hospital Felício Rocho

    RECRUITING

    Belo Horizonte, 30110-934, Brazil

  • Hospital Mater Dei Contorno

    RECRUITING

    Belo Horizonte, 30110-064, Brazil

  • Hospital Maternidade e Pronto Socorro Santa Lucia

    RECRUITING

    Pocos de Calda, 37706-106, Brazil

  • Hospital Moinhos de Vento (HMV)

    RECRUITING

    Porto Alegre, 90035-902, Brazil

  • Hospital Parana - Parana Medical Research Center

    RECRUITING

    Maringá, 87015-000, Brazil

  • Hospital Vera Cruz

    RECRUITING

    Belo Horizonte, 30190-130, Brazil

  • Hospital da Mater Dei Salvador

    RECRUITING

    Salvador, 40221-500, Brazil

  • Hospital e Maternidade Angelina Caron

    RECRUITING

    Campina Grande do Sul, 83434-286, Brazil

  • Instituto Conceive Ltda

    RECRUITING

    São Paulo, 04005-004, Brazil

  • Instituto de Molestias Cardiovasculares Tatui

    RECRUITING

    Tatuí, 18270-170, Brazil

  • Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - InCor HCFMUSP

    RECRUITING

    São Paulo, 05403-000, Brazil

  • Pontificia Universidade Catolica do Parana-(PUCPR)

    RECRUITING

    Curitiba, 80215-901, Brazil

  • The University of Hong Kong, Queen Mary Hospital

    RECRUITING

    Hong Kong, Hong Kong

  • Universidade de Caxias do Sul (UCS)

    RECRUITING

    Caixias Do Sul, 95070-561, Brazil

  • Universidade de Sao Paulo (USP) - Hospital das Clinicas da Faculdade de Medicina

    RECRUITING

    São Paulo, 05403-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.